EGFR and non-small cell lung carcinoma: In the 2011 Chinese edition of NCCN clinical practice guidelines of NSCLC, TKIs has been revised as first line therapy according to the latest randomized phase III studies such as IPASS, First-SIGNAL, WJTOG3405, OPTIMAL, and the presence of EGFR-activating mutation represents critical biological factor for proper patient selection [5-11].